Livia Garzia and team uncover epigenetic drivers of bone cancer that that may help refine prognosis and guide new therapeutic options for chemoresistant tumours
Researchers led by Livia Garzia, PhD, Nada Jabado, MD, PhD, scientists at The Research Institute of the McGill University Health Centre (The Institute) and Claudia Kleinman, PhD, from the Lady Davis Institute for Medical Research (LDI), have uncovered new molecular features of osteosarcoma, the most prevalent bone cancer that mainly affects children and adolescents. Published in Nature Communications, the study identifies new disease mechanisms central to osteosarcoma biology and suggests new therapeutic avenues to explore.